The FDA has granted fast track status to Bristol-Myers Squibb‘s ixabepilone, an epothilone B analog. Ixabepilone has been submitted as a monotherapy to treat patients with metastatic or locally advanced breast cancer after failure of an anthracycline, a taxane, and capecitabine and in combination with capecitabine to treat patients with metastatic or locally advanced breast cancer after failure of an anthracycline and a taxane. The company remarked that there are few proven treatment o...